secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-059031
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio Q1 net loss $7.7M; cash $89.8M, closes $112.5M placement, appoints CEO
-------------------------------------------------------------------------------

- Net loss $7.7M vs $9.6M prior year; cash $89.8M at March 31, 2024.
- Closed oversubscribed $112.5M private placement in April 2024 from institutional investors.
- Appointed Robert Lisicki as CEO and Kiran Nistala as CMO.
- On track for Phase 2 trials: tibulizumab in SSc Q4 2024, HS Q2 2025.
- Cash runway extended through 2027 with placement factored in.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465924059031/0001104659-24-059031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465924059031/tm2413941d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer